首页> 美国卫生研究院文献>Neuro-Oncology >RT-33OUTCOME OF GLIOBLASTOMA IN THE POST-STUPP ERA: A SINGLE CENTRE RETROSPECTIVE AUDIT
【2h】

RT-33OUTCOME OF GLIOBLASTOMA IN THE POST-STUPP ERA: A SINGLE CENTRE RETROSPECTIVE AUDIT

机译:RT-33溶栓后时代胶质母细胞瘤的结果:单中心回顾性审计

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: Glioblastoma is the most common primary brain tumour in adults. Prior to the introduction of the Stupp protocol an audit by the Northern Centre for Cancer Care (NCCC) found a mean survival time of 12.4 months [1] using the standard regime at the time of radiotherapy alone (comparing favorably to Stupp control group under the same regime). However in 2005, Stupp et. al demonstrated an increase in mean survival time in their data from 12.1 months to 14.6 months with a new regime of radical radiotherapy with concurrent and adjuvant chemotherapy using temozolomide [2]. In 2009/2010 this protocol was implemented locally. AIMS: Assess whether expected life expectancy is being achieved as per the Stupp chemoradiotherapy regime standard [2]. METHODS: Retrospective study with data from electronic notes of 105 consecutive patients over 18 years of age who began radical therapy for glioblastoma (Grade 4) between December 2009 – December 2013. Mean survival calculated from surgery date of patients. Age range of the patients was 19-70 years with a median age of 54.85 years. RESULTS: Mean survival time 19 months (±2.3) (range: 4-44+ months). 6, 12, 18 and 24 month survival times were 92.8%, 71.9%, 50.4% and 35.8% respectively. CONCLUSIONS: Mean survival time and 6, 12, 18 and 24 month percentage survival exceeds Stupp data and previous departmental audit, demonstrating the success of the unit.
机译:背景:成胶质细胞瘤是成人中最常见的原发性脑肿瘤。在引入Stupp方案之前,由北部癌症护理中心(NCCC)进行的审计发现,仅在放疗时使用标准方案的平均生存时间为12.4个月[1](相比于Stupp对照组,相同的制度)。然而在2005年,Stupp等。等人证明,采用一种新的放射疗法联合替莫唑胺联合辅助化疗,其平均生存时间从12.1个月增加到14.6个月[2]。在2009/2010年,该协议在本地实施。目的:根据Stupp放化疗方案标准[2]评估是否达到预期寿命。方法:回顾性研究来自于2009年12月至2013年12月之间开始接受胶质母细胞瘤根治性治疗(4级)的18岁以上连续105例患者的电子笔记数据。根据患者的手术日期计算平均生存率。患者的年龄范围为19-70岁,中位年龄为54.85岁。结果:平均生存时间为19个月(±2.3)(范围:4-44 +个月)。 6、12、18和24个月的生存时间分别为92.8%,71.9%,50.4%和35.8%。结论:平均生存时间以及6、12、18和24个月的生存百分比超过了Stupp数据和先前的部门审核,证明了该部门的成功。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号